FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to haematology, and can be used for treating the patients suffering acquired aplastic anaemia. That is ensured by integrated treatment including administration of cyclosporine (CS), methylprednisolone (MP) and immunosuppressor - cyclophosphamide, combined with splenectomy. Also, splenectomy is performed.
EFFECT: method provides higher clinical effectiveness and reduced length of treatment.
4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF CLINICAL COURSE OF ATROPHIC ANAEMIA FOLLOWING SPLENECTOMY | 2013 |
|
RU2535059C1 |
| METHOD FOR PREDICTION OF COURSE OF ATROPHIC ANAEMIA AFTER SPLENECTOMY ON INDEX OF RATIO OF MASS OF CD4+/CD8+T-LYMPHOCYTES SPLEEN | 2015 |
|
RU2594119C1 |
| METHOD FOR PREDICTION OF CLINICAL COURSE OF ATROPHIC ANAEMIA AFTER SPLENECTOMY AFTER SPLENECTOMY BASED ON SPLEEN CD4+LYMPHOCYTES WEIGHT | 2016 |
|
RU2625036C1 |
| METHOD OF TREATMENT OF PATIENTS ILL WITH HYPOPLASTIC ANEMIA | 0 |
|
SU1152575A1 |
| METHOD FOR DIAGNOSING APLASTIC ANEMIA | 2022 |
|
RU2797689C1 |
| METHOD OF EARLY DIAGNOSTICS OF RECURRENCE OF ACUTE LYMPHOBLAST LEUKOSIS IN CHILDREN | 1992 |
|
RU2085943C1 |
| MEANS FOR CORRECTION OF VIOLATIONS IN HEMOGENESIS ERYTHROID LINEAGE CAUSED BY CYSTOSTATIC IMPACT | 2016 |
|
RU2634572C1 |
| METHOD FOR PREDICTING MYELODYSPLASTIC SYNDROME DEVELOPMENT COURSE | 2000 |
|
RU2213975C2 |
| METHOD FOR DETERMINING IMMUNODEPRESSANT THERAPY TACTICS IN THE CASES OF MYELODYSPLASTIC SYNDROME | 2000 |
|
RU2212037C2 |
| METHOD OF MORPHOMETRIC ESTIMATION OF PROGNOSIS OF COURSE OF APLASTIC ANAEMIA AFTER SPLENECTOMY | 2014 |
|
RU2555355C1 |
